Supplemental Figure 1: Relationship of IGF-1 Standard Deviation Z-score with the Anti-
Inflammatory Cytokine IL-10 in HIV. IL-10 was compared among HIV-infected subjects with
IGF-1 below the age- and sex-adjusted population mean (z-score < 0) to those with IGF-1 greater
than or equal to the population mean (z-score 0). In contrast to the relationship between IGF-1
and monocyte/macrophage activation markers in HIV, IL-10 was not higher among individuals
with low IGF-1, and in fact tended toward the opposite direction (P = 0.13). The box spans the
25
thto 75
thpercentiles, whereas whiskers designate the 10
thto 90
thpercentiles.
P-value wasdetermined using Wilcoxon rank-sum test.
Supplemental Table 1: Characteristics of HIV-Infected Participants and Uninfected Controls
HIV (n = 131) Non-HIV (n = 65) P-value
Demographics
Age (y) 46.7 ± 8.2 45.4 ± 7.1 0.25
% Male 67 62 0.44
% Race 0.43
White 52 52
Asian 1 5
Black/African American 33 31
American Indian/ Alaskan Native 3 3
Hispanic 10 6
% Current smoker 34 35 0.83
Alcohol, current avg/month 0.5 [0, 6.4] 2.0 [0, 13.0] 0.25
% History of IVDU 6 8 0.74
% Statin use 17 5 0.02
% CMV IgG seropositivity 89 72 0.002
Metabolic Parameters
IGF-1 z-score -0.09 ± 0.8 -0.3 ± 0.7 0.11
BMI (kg/m2) 27.7 ± 5.5 27.3 ± 5.0 0.63
% BMI category (kg/m2) 0.60
Obese 30 23
Overweight 37 41
VAT (cm2) 111 [66, 221] 105 [53, 179] 0.31
SAT (cm2) 201 [137, 307] 235 [145, 342] 0.34
HIV-Related Parameters
Duration since HIV diagnosis (y) 14.4 ± 6.9 CD4+ T-cell count (#/mm3) 556 [392, 816]
CD8+ T-cell count (#/mm3) 806 [580, 1068]
% Viral load undetectable 75
% Current ART 81
% ART regimen
NRTI only 7
NRTI + NNRTI only 32
NRTI + PI only 39
NNRTI + NRTI + PI 5
Other regimen 17
Immunologic Parameters
hs CRP (mg/L) 1.8 [0.6, 4.3] 1.6 [0.7, 3.7] 0.45
MCP-1 (pg/mL) 261 [179, 359] 223 [166, 271] 0.01
hs IL-6 (pg/mL) 1.1 [0.7, 1.9] 0.9 [0.6, 1.5] 0.07
sCD163 (ng/mL) 1081 [711, 1564] 820 [591, 1054] 0.0002
sCD14 (ng/mL) 431 [223, 1692] 327 [162, 1222] 0.08
IL-18 (pg/mL) 247 [181, 319] 197 [142, 246] 0.0002
LPS (EU/ml) 0.8 [0.4, 1.1] 0.7 [0.3, 0.9] 0.05
Values are reported as mean ± standard deviation if normally distributed and median [interquartile range] if not normally distributed. Bold text denotes statistical significance with P < 0.05.
IVDU, intravenous drug use; CMV IgG, cytomegalovirus immunoglobulin G; IGF-1, insulin-like growth factor 1; BMI, body mass index; VAT, visceral adipose tissue area; SAT, subcutaneous adipose tissue area; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; hs CRP, high sensitivity C-reactive protein; MCP-1, monocyte chemoattractant protein-1; hs IL-6, high sensitivity interleukin-6; sCD163, soluble CD163; sCD14, soluble CD14; IL-18, interleukin-18; LPS, lipopolysaccharide.
Supplemental Table 2: Association of IGF-1 Z-score with Inflammatory Markers in HIV-Infected Participants and Uninfected Controls
Inflammatory Marker HIV (n = 131) Non-HIV (n = 65)
r P-value r P-value
log hs CRP (mg/L) -0.12 0.20 -0.10 0.45
log MCP-1 (pg/mL) -0.02 0.87 0.22 0.09
log hs IL-6 (pg/mL) -0.27 0.006 -0.22 0.13
log sCD163 (ng/mL) -0.28 0.002 -0.16 0.22
log sCD14 (ng/mL) -0.29 0.002 -0.15 0.26
log IL-18 (pg/mL) 0.11 0.22 -0.009 0.95
log LPS (EU/ml) 0.11 0.28 -0.03 0.84
Results are reported as Pearson correlation coefficient r and P-value. Bold text denotes statistical significance with P
< 0.05.
hs CRP, high sensitivity C-reactive protein; MCP-1, monocyte chemoattractant protein-1; hs IL-6, high sensitivity interleukin-6; sCD163, soluble CD163; sCD14, soluble CD14; IL-18, interleukin-18; LPS, lipopolysaccharide.
